NEUP earnings analysis
What we found in NEUP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Neuphoria Therapeutics Inc. reported a significant decline in revenue, dropping to $0 for Q3 2026, compared to $15 million in Q3 2025. The company also recorded a net loss of $0.5 million for the quarter versus a net income of $11.3 million in the prior year, highlighting ongoing financial challenges and an accumulated deficit of $186.9 million. Cash used in operating activities increased to approximately $13.6 million, signaling a substantial cash burn rate.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Plummets to $0
- Revenue for Q3 2026 was $0, a decrease of $15 million from $15 million in Q3 2025.
- Widening Net Loss
- The company incurred a net loss of $0.5 million in Q3 2026, compared to a net income of $11.3 million in Q3 2025.
- Operational Cash Burn Increases
- Cash used in operating activities was $13.6 million for the nine months ended March 31, 2026, compared to $3.7 million in the prior period.
- Higher Restructuring Costs
- Restructuring costs incurred during the nine months were $1.3 million due to paused R&D activities.
- Operating Loss Significantly Higher
- Income (loss) before income taxes for Q3 was a loss of $539,856, down from an income of $11.2 million in Q3 2025.
- Accumulated Deficit Continues to Grow
- As of March 31, 2026, Neuphoria reported an accumulated deficit of $186.9 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Funding Shortfalls
- The company faces ongoing capital needs and states they may finance operations through further equity sales or debt, risking dilution.
- Failed Clinical Trials Impact
- The discontinuation of the SAD program after failing Phase 3 trials may affect long-term viability and investor confidence.
- Uncertainty of Strategic Alternatives
- Neuphoria's future depends on potential strategic transactions, which may not materialize, jeopardizing further development efforts.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.56
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 17, 2026
- Neuphoria Therapeutics Inc. reported significant financial challenges in its Q2 2026 10-Q, showcasing a revenue decline to $0 amidst continued funding from equity sales. The company faced an accumulated deficit of…
- 10-Q · November 14, 2025
- Neuphoria Therapeutics Inc. reported a challenging quarter with a significant net loss of $9.9 million for the three months ending September 30, 2025, up from a loss of $0.8 million in the prior year. Revenue figures…
- 10-K · September 29, 2025
- Neuphoria Therapeutics Inc. reported a net loss of $0.4 million for the fiscal year ending June 30, 2025, compared to a loss of $15.5 million in the previous year, reflecting improvements largely due to milestone…
- 10-Q · May 20, 2025
- Neuphoria's Q1 2025 report shows a significant revenue increase driven by milestone payments from collaboration agreements, resulting in a net income of $11.3 million. The company reported improved cash flow metrics…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NEUP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever